Spectrum and transferability of β-lactam resistance in hospital strains of Enterobacter isolated in Bratislava and Innsbruck

International Journal of Antimicrobial Agents

Volumn 16, Issue 1, 2000, Pages 31-36

  Bujdakova H ^a   Klimackova J ^a   Allerberger, F ^b   Moravcikova M ^a   Bagova M ^c   Hanzen, J ^d   Michalkova Papajova D ^a   Dierich, M P ^b   Kettner, M ^a  

^a Faculty of Natural Sciences   (Slovakia)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c Public Health Authority of the Slovak Republic   (Slovakia)

^d HPL spol s ro   (Slovakia)

Author keywords

Enterobacter; Transferable resistance; Lactam antibiotics

Indexed keywords

AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; IMIPENEM; OUTER MEMBRANE PROTEIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRIA; BACTERIUM CONJUGATION; BACTERIUM ISOLATE; ENTEROBACTER; ESCHERICHIA COLI; HOSPITAL INFECTION; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SLOVAKIA;

EID: 0343877214     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00195-3     Document Type: Article

References (43)

1. Arpin C., Coze C., Rogues A.M., Gachie J.P., Bebear C., Quentin C. Epidemiological study of an outbreak due to multidrug-resistant Enterobacter aerogenes in medical intensive care unit. J. Clin. Microbiol. 34:1996;2163-2169.
2. Neuwirth C., Siebor E., Lopez J., Pechinot A., Kazmierczak A. Outbreak of TEM-24-producing Enterobacter aerogenes in an intensive care unit and dissemination of the extended spectrum β-lactamase to other members of the family Enterobacteriaceae. J. Clin. Microbiol. 34:1996;76-79.
3. Allerberger F., Koeuth T., Lass-Flörl C., et al. Epidemiology of infections due to multiresistant Enterobacter aerogenes in a university hospital. Eur. J. Clin. Microbiol. Infect. Dis. 15:1996;517-521.
4. Maniatis A.N., Trougakos I.P., Katsanis G., Palermos J., Maniatis N.A., Legakis N.J. Changing patterns of bacterial nosocomial infections - a 9 year study in a general hospital. Chemotherapy. 43:1997;69-76.
5. Hanberger H., Garcia-Rodriguez J.A., Gobernado M., Goossens H., Nilsson L.E., Struelens M.J. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. J. Am. Med. Assoc. 6:1999;67-71.
6. Huber T.W., Thomas J.S. Detection of resistance due to inducible β-lactamase in Enterobacter cloacae. J. Clin. Microbiol. 32:1994;481-486.
7. Fung-Tomc J.C., Gradelski E., Huczko E., Dougherty T.J., Kessler R.E., Bonner D.P. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob. Agents Chemother. 40:1996;1289-1293.
8. De Cheldre Y., Maes N., Rost F., De Ryck R., Clevenbergh P., Vincent J.L., Struelens M.J. Molecular epidemiology of an outbreak of multidrug-resistant Enterobacter aerogenes infections and in vivo emergence of imipenem resistance. J. Clin. Microbiol. 35:1997;152-160.
9. Mimoz O., Jacolot A., Padoin Ch., Caillon J., Louchahi K., Tod M., Samii K., Petitjean O. Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivo. J. Antimicrob. Chemother. 39:1997;363-369.
10. Mimoz O., Jacolot A., Leotard S., Hidri N., Samii K., Petitjean O. Efficiencis of cefepime, ceftazidime and imipenem alone and in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or resistant Enterobacter cloacae strains. Antimicrob. Agents Chemother. 42:1998;3304-3308.
11. Medeiros A.A. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin. Infect. Dis. 24:1997;19-45.
12. Pithout J.D., Sanders C.C., Sanders W.E. Jr. Antimicrobial resistance with focus on β-lactam resistance in gram-negative bacilli. Am. J. Med. 103:1997;51-59.
13. Arbo M.D., Hariharan R., Nathan C., Barefoot L., Weinstein R.A., Snydman D.R. Utility of serial rectal swab cultures for detection of ceftazidime- and imipenem-resistant gram-negative bacilli from patients in intensive care unit. Eur. J. Microbiol. Infect. Dis. 17:1998;727-730.
14. Ehrhardt A.F., Sanders Ch.C. β-Lactam resistance among Enterobacter species. J. Antimicrob. Chemother. 32:1993;1-11.
15. Rasmussen B.A., Bush K., Keeney D., Yang Y., Hare R., O'Gara C., Medeiros A.A. Characterization of IMI-1 β-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob. Agents Chemother. 40:1996;2080-2086.
16. Bonfiglio G., Stefani S., Nicoletti G. In vitro activity of cefpirome against β-lactamase-inducible and stably derepressed Enterobacteriaceae. Chemotherapy. 40:1994;311-316.
17. Tejedor-Junco M.T., Gonzales-Martin M., Lupiola P., Gonzales-Lama Z. Type I β-lactamases of Enterobacter cloacae and resistance to β-lactam antibiotics. Folia Microbiol. 43:1998;683-686.
18. Trepanier S., Knox J.R., Clairoux N., Sanschagrin F., Levesque R.C., Huletsky A. Structure-function studies of Ser-289 in the class C β-lactamase from Enterobacter cloacae P99. Antimicrob. Agents Chemother. 43:1999;543-548.
19. Tzouvelekis L.S., Tzelepi E., Mentis A.F., Legakis N.J. In vitro activity of cefpirome against selected clinical enterobacterial isolates with β-lactamase-mediated resistance. Infection. 23:1995;384-387.
20. Lee E.H., Collatz E., Poglajen I., Gutmann L. A rob-like gene of Enterobacter cloacae affecting porin synthesis and susceptibility to multiple antibiotics. Antimicrob. Agents Chemother. 40:1996;2029-2033.
21. Charrel R.N., Pages J.M., De Micco P., Mallea M. Prevalence of outer membrane porin alteration in β-lactam-antibiotic-resistant Enterobacter aerogenes. Antimicrob. Agents Chemother. 40:1996;2854-2858.
22. Nagy E., Pragai Z., Hajdu E., Fodor E. Investigation of the presence of different broad-spectrum β-lactamases among clinical isolates of Enterobacteriaceae. Acta Microbiol. Immunol. Hung. 45:1998;433-446.
23. Lindberg F., Normark S. Contribution of chromosomal β-lactamases to β-lactam resistance in Enterobacteria. Rev. Infect. Dis. 8:1986;292-304.
24. Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A2. 2nd ed. 1990;National Committee for Clinical Laboratory Standards, Vilanova, PA.
25. Bujdáková H., Laušová A., Jankovičová S., Prodinger W.M., Kallová J., Milošovič P., Kettner M. Study of β-lactam resistance in ceftazidime-resistant clinical isolates of Enterobacteriaceae. Int. J. Antimicrob. Agents. 10:1998;135-141.
26. Takahashi S., Nagano Y. Rapid procedure for isolation of plasmid DNA and application to epidemiological analysis. J. Clin. Microbiol. 20:1984;608-613.
27. Schindler P., Huber G. Use of PADAC, a novel chomogenic β-lactamase substrate, for the detection of β-lactamase producing organisms and assay of β-lactamase inhibitors/inactivators. Urs B. Enzyme Inhibitors. 1980;169-176 Weinheim, Germany.
28. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with folin phenol reagent. J. Biol. Chem. 193:1951;256-272.
29. Jarlier V., Nicolas M., Fournier G., Philippon A. Extended broad-spectrum β-lactamases conferring transferable β-lactam resistance to newer agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 10:1988;867-878.
30. Masuda N., Sakagawa E., Ohya S. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1995;645-649.
31. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
32. Barber M., Whitehead J.M.E. Bacteriophage types in penicillin-resistant staphylococcal infection. Br. Med. J. 2:1953;565-569.
33. Sirot D.L., Goldstein F.W., Soussy C.J., et al. Resistance to cefotaxime and seven other β-lactams in members of the family Enterobacteriaceae: a 3-year survey in France. Antimicrob. Agents Chemother. 36:1992;1677-1681.
34. Finnstrom O., Isaksson B., Haeggman S., Burman L.G. Control of an outbreak of a highly β-lactam-resistant Enterobacter cloacae strain in a neonatal special care unit. Acta Paediatr. 87:1998;1070-1074.
35. Füssle R., Biscoping J., Behr R., Sziegoleit A. Development of resistance by Enterobacter cloacae during therapy of pulmonary infections in intensive care patients. Clin. Invest. 72:1994;1015-1019.
36. Rains Ch.P., Bryson H.M., Peters D.H. Ceftazidime. An uptake of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 49:1995;577-617.
37. Babálová M., Blahová J., Lešická-Hupková M., Králiková K., Krčméry V., Purgelová A., Baníková I. Transferable resistance to cefotaxime and other antibiotics in nosocomial strains of Serratia marcescens, Proteus mirabilis and Enterobacter cloacae. Antiinfect. Drugs Chemother. 13:1995;177-178.
38. Milošovič P., Kettner M. Susceptibility of clinical bacterial isolates to amikacin, ceftazidime and ciprofloxacin in Slovakia in the recent period. Antiinfect. Drugs Chemother. 13:1995;95-97.
39. Jacoby G.A. Genetics of extended-spectrum β-lactamases. Eur. J. Clin. Microbiol. Infect. Dis. 1:1994;2-11.
40. Matsumoto Y., Inoue M. Characterization of SFO-1, a plasmid-mediated inducible class A β-lactamase from Enterobacter cloacae. Antimicrob. Agents Chemother. 43:1999;307-313.
41. Bush K. Is it important to identify extended-spectrum β-lactamase-producing isolates? Eur. J. Clin. Microbiol. Infect. Dis. 15:1996;361-364.
42. Garau J. Clinical strategies for serious infections: a European perspective. Diagn. Microbiol. Infect. Dis. 31:1998;397-404.
43. Grimm H., Halle E., Kazser F.H., Ullmann U., Wiedemann B. Parenterale Antibiotika bei Erwachsenen. Mikrobiol. Chemother. J. 8:1999;8-10.